Max Stock Ltd. to Host First Quarter 2024 Earnings Conference Call on May 22, 2024
- 45
PR Newswire
CAESAREA, Israel, May 9, 2024
CAESAREA, Israel, May 9, 2024 /PRNewswire/ -- Max Stock Limited (TASE: MAXO) (the "Company") today announced it will host a conference call (LINK) on May 22, 2024 at 7:30 a.m. Eastern Time / 2:30 p.m. IL to discuss its first quarter 2024 financial results.
Nir Dagan, Deputy CEO and Head of Finance, and Talia Sessler, Chief Corporate Development and IR Officer, will host the call followed by Q&A.
The conference call will also be accessible at https://ir.maxstock.co.il/en/event-en/.
There will be a slide presentation that accompanies the call. The slides will be accessible at https://ir.maxstock.co.il/en/presentation-en/.
An archived webcast of the conference call will be available at https://ir.maxstock.co.il/en/presentation-en/.
This is an English translation of segments of a Hebrew immediate report that was published on May 9 2024 (Ref. No: 2024-01-048708) (hereinafter: the "Hebrew Version"). This English version is only for convenience purposes. This is not an official translation and has no binding force. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.
About Max Stock
Max Stock is Israel's leading extreme value retailer, currently present in 64 locations throughout Israel and 2 locations in Portugal that opened in 2023. We offer a broad assortment of quality products for customers' everyday needs at affordable prices, helping customers "Dream Big, Pay Small". For more information, please visit https://ir.maxstock.co.il
Company Contacts:
Talia Sessler,
Chief Corporate Development and IR Officer
[email protected]
View original content:https://www.prnewswire.com/news-releases/max-stock-ltd-to-host-first-quarter-2024-earnings-conference-call-on-may-22-2024-302141273.html
SOURCE Max Stock Limited
PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of N-able, Inc. (NYSE: NABL) and Encourages Shareholders to Contact the Firm for Additional Information
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
- Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response